Biomarkers /
STK11
Overview
Serine/threonine kinase 11 (STK11) is a gene that encodes a protein that belongs to the serine/threonine kinase family. The protein functions in the regulation of cell polarity and is also a tumor suppressor. Missense mutations, nonsense mutations, silent mutations, whole gene deletions, frameshift deletions and insertions, and in-frame deletions are observed in cancers such as cervical cancer, gastrointestinal cancer, and lung cancer.
STK11 is altered in 3.04% of all cancers with lung adenocarcinoma, breast invasive ductal carcinoma, non-small cell lung carcinoma, colon adenocarcinoma, and adenocarcinoma of unknown primary having the greatest prevalence of alterations [3].
The most common alterations in STK11 are STK11 Mutation (1.76%), STK11 Loss (0.31%), STK11 X155_splice (0.10%), STK11 Amplification (0.11%), and STK11 X200_splice (0.07%) [3].
Clinical Trials
Significance of STK11 in Diseases
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.